{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:00:31Z","timestamp":1760241631839,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"NSF","doi-asserted-by":"publisher","award":["1722906","1722665"],"award-info":[{"award-number":["1722906","1722665"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.idc.2018.02.014","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T18:40:59Z","timestamp":1526496059000},"page":"323-345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Five Questions Concerning Managing Hepatitis C in the Justice System"],"prefix":"10.1016","volume":"32","author":[{"given":"Anne C.","family":"Spaulding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeline G.","family":"Adee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagpreet","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"von Oehsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.idc.2018.02.014_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2018.02.014_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005053-199201000-00010","article-title":"Characteristics of intravenous drug users by history of arrest and treatment for drug use","volume":"180","author":"Alcabes","year":"1992","journal-title":"J\u00a0Nerv Ment Dis"},{"issue":"7","key":"10.1016\/j.idc.2018.02.014_bib3","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/add.12938","article-title":"Incarceration and injection drug use in Baltimore, Maryland","volume":"110","author":"Genberg","year":"2015","journal-title":"Addiction"},{"year":"2017","series-title":"A\u00a0national strategy for the elimination of hepatitis B and C: phase two report","key":"10.1016\/j.idc.2018.02.014_bib4"},{"key":"10.1016\/j.idc.2018.02.014_bib5","unstructured":"World prison brief, Webpage of the International Centre for Prison Studies, University of London. Available at: http:\/\/www.prisonstudies.org\/world-prison-brief-data. Accessed February 3, 2018."},{"issue":"Suppl 1","key":"10.1016\/j.idc.2018.02.014_bib6","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.2105\/AJPH.2010.300004","article-title":"The diversity of release patterns for jail detainees: implications for public health interventions","volume":"101","author":"Spaulding","year":"2011","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.idc.2018.02.014_bib7","doi-asserted-by":"crossref","first-page":"e0191643","DOI":"10.1371\/journal.pone.0191643","article-title":"Jail, an unappreciated medical home: assessing the feasibility of a strengths-based case management intervention to improve the care retention of HIV-infected persons once released from jail","volume":"13","author":"Spaulding","year":"2018","journal-title":"PLoSOne"},{"issue":"2","key":"10.1016\/j.idc.2018.02.014_bib8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/003335491412900213","article-title":"Hepatitis C seroprevalence among prison inmates since 2001: still high but declining","volume":"129","author":"Varan","year":"2014","journal-title":"Public Health Rep"},{"year":"2016","series-title":"Prisoners in 2015","author":"Carson","key":"10.1016\/j.idc.2018.02.014_bib9"},{"issue":"10","key":"10.1016\/j.idc.2018.02.014_bib10","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1377\/hlthaff.2016.0296","article-title":"New hepatitis C drugs are very costly and unavailable to many state prisoners","volume":"35","author":"Beckman","year":"2016","journal-title":"Health Aff"},{"issue":"1","key":"10.1016\/j.idc.2018.02.014_bib11","first-page":"27","article-title":"Impact of new therapeutics for hepatitis C virus infection in incarcerated populations","volume":"21","author":"Spaulding","year":"2012","journal-title":"Top Antivir Med"},{"issue":"3","key":"10.1016\/j.idc.2018.02.014_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.24875\/AIDSRev.M17000006","article-title":"HIV and HCV in U.S. prisons and jails: the correctional facility as a bellwether over time for the community\u2019s infections","volume":"19","author":"Spaulding","year":"2017","journal-title":"AIDS Rev"},{"year":"2004","series-title":"Hepatitis testing and treatment in state prisons","author":"Beck","key":"10.1016\/j.idc.2018.02.014_bib13"},{"issue":"10","key":"10.1016\/j.idc.2018.02.014_bib14","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003\u20132013","volume":"62","author":"Ly","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2018.02.014_bib15","unstructured":"Estelle v. Gamble 429\u00a0U.S. 97 (1976)."},{"issue":"2","key":"10.1016\/j.idc.2018.02.014_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/M15-0617","article-title":"Prevention of hepatitis C by screening and treatment in US prisons","volume":"164","author":"He","year":"2016","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.idc.2018.02.014_bib17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2018.02.014_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.drugalcdep.2014.11.021","article-title":"High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia","volume":"147","author":"Cepeda","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.idc.2018.02.014_bib19","unstructured":"Federal Bureau of Prisons. Evaluation and management of chronic hepatitis C virus (HCV) infection. Clinical guidance. 2016. Available at: https:\/\/www.bop.gov\/resources\/pdfs\/hepatitis_c.pdf. Accessed September 7, 2017."},{"key":"10.1016\/j.idc.2018.02.014_bib20","unstructured":"Committee on Finance, United States Senate. The price of sovaldi and its impact on the U.S. health care system. 2015. Available at: https:\/\/www.finance.senate.gov\/download\/the-price-of-sovaldi-and-its-impact-on-the-us-health-care-system-full-report. Accessed February 24, 2017."},{"issue":"RR-4","key":"10.1016\/j.idc.2018.02.014_bib21","first-page":"1","article-title":"Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965","volume":"61","author":"Smith","year":"2012","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.idc.2018.02.014_bib22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","article-title":"Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.idc.2018.02.014_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.20502","article-title":"Elevated prevalence of hepatitis C infection in users of United States veterans medical centers","volume":"41","author":"Dominitz","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.idc.2018.02.014_bib24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.idc.2018.02.014_bib25","first-page":"379","article-title":"Comparison of risk-based hepatitis C screening and the true seroprevalence in an urban prison system","volume":"92","author":"Kuncio","year":"2015","journal-title":"J\u00a0Urban Health"},{"issue":"6","key":"10.1016\/j.idc.2018.02.014_bib26","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.2105\/AJPH.2014.301943","article-title":"Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004\u20132012: limitations of 1945\u20131965 birth cohort screening in correctional settings","volume":"106","author":"Larney","year":"2014","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.idc.2018.02.014_bib27","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/0033354916662212","article-title":"Performance of risk-based and birth-cohort strategies for identifying hepatitis C virus infection among people entering prison, Wisconsin, 2014","volume":"131","author":"Stockman","year":"2016","journal-title":"Public Health Rep"},{"year":"2017","series-title":"HIV in prison","author":"Maruschak","key":"10.1016\/j.idc.2018.02.014_bib28"},{"issue":"1","key":"10.1016\/j.idc.2018.02.014_bib29","first-page":"130","article-title":"A\u00a0pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections","volume":"38","author":"Beckwith","year":"2016","journal-title":"J\u00a0Public Health (Oxf)"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2018.02.014_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/00333549071220S216","article-title":"Promoting HCV treatment completion for prison inmates: New York State's hepatitis C continuity program","volume":"122","author":"Klein","year":"2007","journal-title":"Public Health Rep"},{"issue":"11","key":"10.1016\/j.idc.2018.02.014_bib31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","article-title":"Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.idc.2018.02.014_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-138-3-200302040-00010","article-title":"Treatment of chronic hepatitis C in a state correctional facility","volume":"138","author":"Allen","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.idc.2018.02.014_bib33","unstructured":"Assoumou SA, Wang J, Tsui J, et\u00a0al. Characterization of a population with hepatitis C infection in a U.S. state prison. 6th International Symposium on hepatitis care in substance users. Jersey City, NJ, September 6\u20138, 2017."},{"issue":"1","key":"10.1016\/j.idc.2018.02.014_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13027-016-0071-z","article-title":"Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States","volume":"11","author":"Rosenthal","year":"2016","journal-title":"Infect Agent Cancer"},{"issue":"8","key":"10.1016\/j.idc.2018.02.014_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/apt.14271","article-title":"Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6","volume":"46","author":"He","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.idc.2018.02.014_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","article-title":"Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving","volume":"15","author":"Chhatwal","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.idc.2018.02.014_bib37","unstructured":"42\u00a0U.S.C. 1396r-8(k)(1)."},{"key":"10.1016\/j.idc.2018.02.014_bib38","unstructured":"42 C.F.R. 447.504."},{"issue":"7","key":"10.1016\/j.idc.2018.02.014_bib39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2018.02.014_bib40","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.27641","article-title":"Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus","volume":"61","author":"van de Ven","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.idc.2018.02.014_bib41","unstructured":"42\u00a0U.S.C. 1395 w-3a."},{"key":"10.1016\/j.idc.2018.02.014_bib42","unstructured":"38\u00a0U.S.C. 8126."},{"key":"10.1016\/j.idc.2018.02.014_bib43","unstructured":"42\u00a0U.S.C. 256b."},{"key":"10.1016\/j.idc.2018.02.014_bib44","unstructured":"42\u00a0U.S.C. 1396r-8."},{"key":"10.1016\/j.idc.2018.02.014_bib45","unstructured":"42\u00a0U.S.C. 1396r-8 (c)(1)(C)(i)."},{"issue":"1","key":"10.1016\/j.idc.2018.02.014_bib46","first-page":"7","article-title":"A\u00a0prescription for excessive drug pricing: leveraging government patent use for health","volume":"18","author":"Brennan","year":"2016","journal-title":"Yale Journal of Law & Technology"},{"key":"10.1016\/j.idc.2018.02.014_bib47","article-title":"High cost of new HCV drugs strains prison budgets, locks many out of care","author":"Fields","year":"2016","journal-title":"Wall Street Journal"},{"key":"10.1016\/j.idc.2018.02.014_bib48","unstructured":"42 C.F.R. 447.502."},{"key":"10.1016\/j.idc.2018.02.014_bib49","unstructured":"42\u00a0U.S.C. 1396r-8(c)(1)(D)(i)."},{"key":"10.1016\/j.idc.2018.02.014_bib50","unstructured":"42\u00a0U.S.C. 1396r-8(c)(1)(D)(ii)."},{"key":"10.1016\/j.idc.2018.02.014_bib51","unstructured":"Sharfstein JM, GA, JMB, et\u00a0al. Letter to Rebekah E. Gee, Secretary of Health, State of Louisiana. 2017. Available at: http:\/\/ldh.la.gov\/assets\/docs\/HepatitisC\/ResponsememotoSecretaryGeeHCV.pdf. Accessed October 10, 2010."},{"issue":"10","key":"10.1016\/j.idc.2018.02.014_bib52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/cid\/cit069","article-title":"Cost-effectiveness of screening for chronic hepatitis C infection in the United States","volume":"56","author":"Eckman","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2018.02.014_bib53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.idc.2018.02.014_bib54","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.25510","article-title":"Economic model of a birth cohort screening program for hepatitis C virus","volume":"55","author":"McGarry","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.idc.2018.02.014_bib55","doi-asserted-by":"crossref","first-page":"e58975","DOI":"10.1371\/journal.pone.0058975","article-title":"Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.idc.2018.02.014_bib56","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/hep.28497","article-title":"Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis","volume":"63","author":"Martin","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.idc.2018.02.014_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003153","article-title":"Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons","volume":"3","author":"Martin","year":"2013","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.idc.2018.02.014_bib58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/cid\/cix207","article-title":"Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study","volume":"65","author":"Cepeda","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2018.02.014_bib59","unstructured":"Available at: https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/index.html. Accessed March 19, 2018."},{"key":"10.1016\/j.idc.2018.02.014_bib60","unstructured":"42 C.F.R. 447.509 (a) (1)."},{"key":"10.1016\/j.idc.2018.02.014_bib61","unstructured":"42 C.F.R. 447.509."},{"key":"10.1016\/j.idc.2018.02.014_bib62","unstructured":"42 C.F.R. 447.509 (a) (6)."},{"key":"10.1016\/j.idc.2018.02.014_bib63","unstructured":"42\u00a0U.S.C. 1396r-8 (k)(3)."},{"key":"10.1016\/j.idc.2018.02.014_bib64","unstructured":"Veterans Health Care Act of 1992, Pub. L. No. 102-585 \u00a7602, 106 Stat. 4943, 4967\u20134971 (1992)."},{"key":"10.1016\/j.idc.2018.02.014_bib65","unstructured":"42\u00a0U.S.C. 1396\u00a0r -8(c)(1)(C)(ii)(III)."},{"year":"2001","series-title":"Pharmaceutical discounts under federal law: state program opportunities","author":"von Oehsen","key":"10.1016\/j.idc.2018.02.014_bib66"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552018300242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552018300242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:12:35Z","timestamp":1760195555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552018300242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0891552018300242"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2018.02.014","relation":{},"ISSN":["0891-5520"],"issn-type":[{"type":"print","value":"0891-5520"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five Questions Concerning Managing Hepatitis C in the Justice System","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2018.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}